Ebola drug trial: a ray of hope

Letter to Editor

Year 2019, Volume: 44 Issue: 4, 1532 - 1533, 29.12.2019

https://doi.org/10.17826/cumj.517406

-

1. Surender Singh Jadav, Anoop Kumar, Mohamed Jawed Ahsan, Venkatesan Jayaprakash. Ebola Virus: Current and Future Perspectives: Infectious Disorders – Drug Targets, 2015, 15, 20-31
2. John Misasi, Morgan S.A. Gilman, Masaru Kanekiyo, Miao Gui, Alberto Cagigi, Sabue Mulangu et al., Structural and Molecular Basis for Ebola Virus Neutralization by Protective Human Antibodies: Science. 2016 March 18; 351(6279): 1343–1346. doi:10.1126/science.aad6117.
3. Maria L. Agostini, Erica L. Andres, Amy C. Sims, Rachel L. Graham, Timothy P. Sheahan, Xiaotao Lu, et al., Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. mBio 9:e00221-18. https://doi.org/10.1128/mBio.00221-18
4. Vincent Madelain, Sylvain Baize, Frédéric Jacquot, Stéphanie Reynard, Alexandra Fizet, Stephane Barron, et al., Ebola viral dynamics in nonhuman primates provides insights into virus immuno-pathogenesis and antiviral strategies. NATURE COMMUNICATIONS | (2018) 9:4013 | DOI: 10.1038/s41467-018-06215-z.
5. Michael McCarthy. US signs contract with ZMapp maker to accelerate development of the Ebola drug. BMJ 2014;349:g5488 doi: 10.1136/bmj.g5488.
6. Davey RT Jr, Dodd L, Proschan MA, Neaton J, Neuhaus Nordwall J, Koopmeiners JS. A Randomized, Controlled Trial of ZMapp for Ebola Virus Infection. The PREVAIL II Writing Group, for the Multi-National PREVAIL II Study Team. N Engl J Med. 2016 Oct 13;375(15):1448-1456.

Year 2019, Volume: 44 Issue: 4, 1532 - 1533, 29.12.2019

https://doi.org/10.17826/cumj.517406

-

1. Surender Singh Jadav, Anoop Kumar, Mohamed Jawed Ahsan, Venkatesan Jayaprakash. Ebola Virus: Current and Future Perspectives: Infectious Disorders – Drug Targets, 2015, 15, 20-31
2. John Misasi, Morgan S.A. Gilman, Masaru Kanekiyo, Miao Gui, Alberto Cagigi, Sabue Mulangu et al., Structural and Molecular Basis for Ebola Virus Neutralization by Protective Human Antibodies: Science. 2016 March 18; 351(6279): 1343–1346. doi:10.1126/science.aad6117.
3. Maria L. Agostini, Erica L. Andres, Amy C. Sims, Rachel L. Graham, Timothy P. Sheahan, Xiaotao Lu, et al., Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. mBio 9:e00221-18. https://doi.org/10.1128/mBio.00221-18
4. Vincent Madelain, Sylvain Baize, Frédéric Jacquot, Stéphanie Reynard, Alexandra Fizet, Stephane Barron, et al., Ebola viral dynamics in nonhuman primates provides insights into virus immuno-pathogenesis and antiviral strategies. NATURE COMMUNICATIONS | (2018) 9:4013 | DOI: 10.1038/s41467-018-06215-z.
5. Michael McCarthy. US signs contract with ZMapp maker to accelerate development of the Ebola drug. BMJ 2014;349:g5488 doi: 10.1136/bmj.g5488.
6. Davey RT Jr, Dodd L, Proschan MA, Neaton J, Neuhaus Nordwall J, Koopmeiners JS. A Randomized, Controlled Trial of ZMapp for Ebola Virus Infection. The PREVAIL II Writing Group, for the Multi-National PREVAIL II Study Team. N Engl J Med. 2016 Oct 13;375(15):1448-1456.

There are 6 citations in total.

Primary Language	English
Subjects	Clinical Sciences
Journal Section	Letter to the Editor
Authors	Pugazhenthan Thangaraju 0000-0002-4090-2004 Shobanbabu Varthya This is me 0000-0002-7163-0400 Sajitha Venkatesan This is me 0000-0001-9147-2553
Publication Date	December 29, 2019
Acceptance Date	March 16, 2019
Published in Issue	Year 2019 Volume: 44 Issue: 4

MLA	Thangaraju, Pugazhenthan et al. “Ebola Drug Trial: A Ray of Hope”. Cukurova Medical Journal, vol. 44, no. 4, 2019, pp. 1532-3, doi:10.17826/cumj.517406.